抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究

doi:10.12092/j.issn.1009-2501.2019.04.011

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (4): 433-439.doi: 10.12092/j.issn.1009-2501.2019.04.011

抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究

张腾跃¹，杨广山²，马克龙³，范平生¹

安徽省肿瘤医院，中国科学技术大学附属第一医院，中国科学技术大学生命科学与医学部，¹肿瘤内科，²中医科，合肥 230000，安徽；³安徽中医药大学中西医结合临床学院，生物化学教研室，合肥 230000，安徽

收稿日期:2018-11-22 修回日期:2019-03-20 出版日期:2019-04-26 发布日期:2019-05-01
通讯作者: 范平生，男，本科，主任医师，博士生导师，研究方向：肝素抗肿瘤转移的基础与临床研究。 Tel：13956010593 E-mail：fanpingsheng@csco.ac.cn
作者简介:张腾跃，男，博士，主治医师，研究方向：肝素抗肿瘤转移的基础与临床研究。 Tel：13855188692 E-mail：zhty6580@sina.com
基金资助:
安徽省自然科学基金面上项目（1408085QH182）；中国科学技术大学“科大新医学”培育基金（WK9110000024）

Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer

ZHANG Tengyue¹, YANG Guangshan², MA Kelong ³, FAN Pingsheng¹

¹Department of Oncology, ²Department of Chinese Medicine, Anhui Provincial Cancer Hospital, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui, China; ³ Biochemistry Department, Integrated Traditional Chinese and Western Medicine College, Anhui University of Traditional Chinese Medicine, Hefei 230000, Anhui, China

Received:2018-11-22 Revised:2019-03-20 Online:2019-04-26 Published:2019-05-01

摘要/Abstract

摘要：

目的:分析胃癌患者凝血指标与临床病理特征的关系，观察抗凝治疗对高凝状态、肿瘤转移、生存期的影响及安全性评价。方法:选取140例胃癌患者，分析凝血指标与临床病理特征的关系。选取III期胃癌患者172例，分为治疗组（抗凝治疗联合化疗）116例，对照组56例（单用化疗），观察抗凝治疗对高凝状态、肿瘤转移、生存期的影响及安全性评价。结果:淋巴结转移N1-3组较N0组D-二聚体升高（P<0.05），III、IV期较I、II期血浆纤维蛋白原（FIB）、D-二聚体升高，部分活化凝血活酶时间（APTT）数值降低（P<0.05）。治疗组抗凝治疗后，血浆凝血酶原时间（PT）、APTT延长，D-二聚体、FIB降低（P<0.05）。治疗组的12月、24月、36月腹腔淋巴结、肝脏转移率较对照组降低（P<0.05）。治疗组2年、3年生存率高于对照组（P<0.05），中位生存期及无病生存期较对照组延长。两组牙龈出血、血小板减少、皮肤瘀点瘀斑发生率无统计学差异（P>0.05）。结论:胃癌高凝状态影响因素为淋巴结转移、TNM分期偏晚。抗凝治疗可改善高凝状态，降低腹腔淋巴结及肝脏转移率，延长生存期，未增加上述不良反应发生率。

关键词: 抗凝治疗, 胃癌, 高凝状态, 转移, 生存期

Abstract:

AIM: To analyze the relationship between coagulation parameters and clinic pathological features of gastric cancer patients, and observe the effect of anticoagulant therapy on hypercoagulable state, tumor metastasis/recurrence, survival status and safety evaluation of gastric cancer. METHODS: 140 patients with gastric cancer were selected to analyze the relationship between coagulation parameters and clinic pathological features. 172 patients with stage III gastric cancer were enrolled, including 116 patients in the treatment group (prophylactic anticoagulant therapy combined with postoperative adjuvant chemotherapy) and 56 patients in the control group (postoperative adjuvant chemotherapy). The anticoagulant therapy was observed on hypercoagulable state and tumor metastasis/recurrence, impact of survival and safety assessment. RESULTS:D-dimer of lymph node metastasis N1-3 group was higher than N0 group (P<0.05), stage III and IV were higher than stage I and II of FIB, D-dimer, and APTT value was decreased (P<0.05). Before and after anticoagulant therapy in the treatment group, PT and APTT were prolonged, D-dimer and FIB were decreased (P<0.05). The rate of lymph node and liver metastasis in the treatment group was lower than that in the control group in 12, 24 and 36 months (P<0.05). The 2-year and 3-year survival rates of the treatment group were higher than those of the control group (P<0.05), and the median survival and disease-free survival were longer than the control group. There was no significant difference in the incidence of gingival bleeding, thrombocytopenia, and ecchymosis of the skin between the two groups (P>0.05). CONCLUSION:The factors influencing the hypercoagulable state of gastric cancer are lymph node metastasis and TNM staging. Anticoagulant therapy can improve hypercoagulability, reduce the rate of lymph node and liver metastasis, and prolong survival without increasing the incidence of adverse reactions.

Key words: anticoagulant therapy, gastric cancer, hypercoagulable state, metastasis, survival analysis

中图分类号:

R735.2

张腾跃，杨广山，马克龙，范平生. 抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(4): 433-439.

ZHANG Tengyue, YANG Guangshan, MA Kelong, FAN Pingsheng. Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 433-439.

参考文献

［1］Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer ［J］. Tumour Biol, 2017, 39(7): 1010428317714626.
［2］Remiker AS,Palumbo JS.Mechanisms coupling thrombin to metastasis and tumorigenesis［J］.Thromb Res,2018,164 Suppl 1:S29-S33.
［3］Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer ［J］. Ann N Y Acad Sci, 2017, 1404(1): 27-48.
［4］Kwon OK, Kim SW, Chae HD, et al. Validation of the 7th AJCC/UICC staging system for gastric cancer and a proposal for a new TNM system based on a prognostic score: a retrospective multicenter study ［J］. Ann Surg Treat Res, 2016, 91(6): 295-302.
［5］Sun RQ, Yang HF. The application of disseminated intravascular coagulation score in sepsis ［J］. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2009, 21(8): 478-480.
［6］Refaai MA, Riley P, Mardovina T, et al. The clinical significance of fibrin monomers［J］. Thromb Haemost, 2018, 118(11): 1856-1866.
［7］Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon ［J］. Arch Intern Med, 2004, 164(2): 190-194.
［8］Carroll BJ, Piazza G. Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test ［J］? Vasc Med, 2018, 23(4): 388-399.
［9］郑青秀, 徐小小, 刘刚, 等. 补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响［J］.中国临床药理学与治疗学, 2018, 23(6): 694-699.
［10］Martín Guerra JM, Asenjo MM, Dueas Gutiérrez CJ, et al. Synchronous cardiopulmonary consequences of the hypercoagulable state associated with cancer ［J］. Arch Bronconeumol, 2018, pii: S0300-2896(18)30328-4.
［11］De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms ［J］. Crit Rev Oncol Hematol, 2004, 50(3): 187-196.
［12］Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer ［J］. J Clin Oncol, 2009, 27(29): 4874-4880.
［13］王洛波, 王兵,丁语, 等. 利伐沙班和华法林治疗下肢深静脉血栓形成的疗效比较［J］. 医药导报, 2016, 35(10): 1089-1091.
［14］Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer［J］. J Clin Oncol, 2007, 25(34): 5490-5505.
［15］Remiker AS, Palumbo JS. Mechanisms coupling thrombin to metastasis and tumorigenesis［J］. Thromb Res, 2018, 164 Suppl 1: S29-S33.
［16］Smorenburg SM, Van Noorden CJ. The compex effects of heparins on cancer progression and metastasis in experimental studies ［J］. Pharmacol Rev, 2001, 53(1): 932105
［17］Kragh M, Binderup L, Vig Hjarnaa PJ, et al. Non-anti-coagulant heparin Inhibits metastasis but not primary tumor growth ［J］. Oncol Rep, 2005, 14 (1) : 992104.
［18］Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemicallymodified heparin with reduced anticoagulant activity ［J］. Cancer Lett, 2004, 207(2): 1652174
［19］Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)［J］. J Clin Oncol, 2004, 22(10): 1944-1948.
［20］椰慧楠, 王哲, 汪忠淼. 低分子肝素对恶性肿瘤患者血液高凝状态以及生存率的影响［J］. 疑难病杂志, 2016, 15(3): 273-275,279.

[1]	王艳, 张金辉, 赵永辰, 刘宏祥, 刘亚维, 苗欢欢, 杨信才. 红杉黄酮通过下调PI3K/AKT信号通路抑制胃癌细胞增殖侵袭等干细胞特性[J]. 中国临床药理学与治疗学, 2023, 28(5): 508-513.
[2]	封壮壮, 宋瑞平, 豆鹏程, 陈心怡, 左娇娇, 舒劲. 基于mTOR/Beclin1/LC3信号轴探讨制萎扶胃丸对胃癌前病变大鼠胃窦组织自噬的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 361-370.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[5]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[6]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[7]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[8]	郭胜杰, 管汐蕊, 曹文莉, 梁思成, 齐晓怡, 葛广波, 吕沐瀚. 尿苷二磷酸葡醛酸转移酶介导的胆汁酸代谢过程及其内源和外源影响因素研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 102-107.
[9]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[10]	江玉华, 支慧, 卢林明, 田大皓, 王晓庆, 葛钰, 谢尚富, 王琪. 皖南蝮蛇毒抑瘤组分-I逆转原代胃癌相关成纤维细胞促癌作用[J]. 中国临床药理学与治疗学, 2021, 26(4): 389-394.
[11]	帕孜来提·亚森, 袁浩, 路红, 郑亚, 王玉平, 周永宁. 胃癌靶向治疗药物临床实验研究进展[J]. 中国临床药理学与治疗学, 2021, 26(4): 454-461.
[12]	赵嫄, 聂倩文, 尹江燕, 郇轩, 田梅香, 张正义. 赖氨酸乙酰化的动态调节在心脏疾病中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1186-1192.
[13]	宋丹丹, 陈雪源, 陈瑞琪, 李涵乔, 吴甜. 长链非编码RNA MALAT1在乳腺癌中的研究现状[J]. 中国临床药理学与治疗学, 2021, 26(1): 49-57.
[14]	吴懿, 朱阿考, 单毓强, 应荣超, 金慧成. 白藜芦醇调控miR-409-3p/FKBP14抑制胃癌细胞BGC823恶性进程[J]. 中国临床药理学与治疗学, 2020, 25(9): 968-975.
[15]	张雪婷, 周昕, 胡旭, 解雪峰. 转移照护中的药品风险管理[J]. 中国临床药理学与治疗学, 2020, 25(7): 784-790.

抗凝治疗对中晚期胃癌改善高凝状态、抗肿瘤转移的临床研究

Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价